Patent Grant
7813812
The present invention generally relates to medical devices and methods of use for the treatment and/or management of cardiovascular and renal disorders. Specifically, the present invention relates to devices and methods for controlling the baroreflex system for the treatment and/or management of cardiovascular and renal disorders and their underlying causes and conditions.
Cardiovascular disease is a major contributor to patient illness and mortality. It also is a primary driver of health care expenditure, costing more than $326 billion each year in the United States. Hypertension, or high blood pressure, is a major cardiovascular disorder that is estimated to affect over 50 million people in the United Sates alone. Of those with hypertension, it is reported that fewer than 30% have their blood pressure under control. Hypertension is a leading cause of heart failure and stroke. It is the primary cause of death in over 42,000 patients per year and is listed as a primary or contributing cause of death in over 200,000 patients per year in the U.S. Accordingly, hypertension is a serious health problem demanding significant research and development for the treatment thereof.
Hypertension occurs when the body's smaller blood vessels (arterioles) constrict, causing an increase in blood pressure. Because the blood vessels constrict, the heart must work harder to maintain blood flow at the higher pressures. Although the body may tolerate short periods of increased blood pressure, sustained hypertension may eventually result in damage to multiple body organs, including the kidneys, brain, eyes and other tissues, causing a variety of maladies associated therewith. The elevated blood pressure may also damage the lining of the blood vessels, accelerating the process of atherosclerosis and increasing the likelihood that a blood clot may develop. This could lead to a heart attack and/or stroke. Sustained high blood pressure may eventually result in an enlarged and damaged heart (hypertrophy), which may lead to heart failure.
Heart failure is the final common expression of a variety of cardiovascular disorders, including ischemic heart disease. It is characterized by an inability of the heart to pump enough blood to meet the body's needs and results in fatigue, reduced exercise capacity and poor survival. It is estimated that approximately 5,000,000 people in the United States suffer from heart failure, directly leading to 39,000 deaths per year and contributing to another 225,000 deaths per year. It is also estimated that greater than 400,000 new cases of heart failure are diagnosed each year. Heart failure accounts for over 900,000 hospital admissions annually, and is the most common discharge diagnosis in patients over the age of 65 years. It has been reported that the cost of treating heart failure in the United States exceeds $20 billion annually. Accordingly, heart failure is also a serious health problem demanding significant research and development for the treatment and/or management thereof.
Heart failure results in the activation of a number of body systems to compensate for the heart's inability to pump sufficient blood. Many of these responses are mediated by an increase in the level of activation of the sympathetic nervous system, as well as by activation of multiple other neurohormonal responses. Generally speaking, this sympathetic nervous system activation signals the heart to increase heart rate and force of contraction to increase the cardiac output; it signals the kidneys to expand the blood volume by retaining sodium and water; and it signals the arterioles to constrict to elevate the blood pressure. The cardiac, renal and vascular responses increase the workload of the heart, further accelerating myocardial damage and exacerbating the heart failure state. Accordingly, it is desirable to reduce the level of sympathetic nervous system activation in order to stop or at least minimize this vicious cycle and thereby treat or manage the heart failure.
A number of drug treatments have been proposed for the management of hypertension, heart failure and other cardiovascular disorders. These include vasodilators to reduce the blood pressure and ease the workload of the heart, diuretics to reduce fluid overload, inhibitors and blocking agents of the body's neurohormonal responses, and other medicaments.
Various surgical procedures have also been proposed for these maladies. For example, heart transplantation has been proposed for patients who suffer from severe, refractory heart failure. Alternatively, an implantable medical device such as a ventricular assist device (VAD) may be implanted in the chest to increase the pumping action of the heart. Alternatively, an intra-aortic balloon pump (IABP) may be used for maintaining heart function for short periods of time, but typically no longer than one month. Other surgical procedures are available as well.
It has been known for decades that the wall of the carotid sinus, a structure at the bifurcation of the common carotid arteries, contains stretch receptors (baroreceptors) that are sensitive to the blood pressure. These receptors send signals via the carotid sinus nerve to the brain, which in turn regulates the cardiovascular system to maintain normal blood pressure (the baroreflex), in part through activation of the sympathetic nervous system. Electrical stimulation of the carotid sinus nerve (baropacing) has previously been proposed to reduce blood pressure and the workload of the heart in the treatment of high blood pressure and angina. For example, U.S. Pat. No. 6,073,048 to Kieval et al. discloses a baroreflex modulation system and method for stimulating the baroreflex arc based on various cardiovascular and pulmonary parameters.
Although each of these alternative approaches is beneficial in some ways, each of the therapies has its own disadvantages. For example, drug therapy is often incompletely effective. Some patients may be unresponsive (refractory) to medical therapy. Drugs often have unwanted side effects and may need to be given in complex regimens. These and other factors contribute to poor patient compliance with medical therapy. Drug therapy may also be expensive, adding to the health care costs associated with these disorders. Likewise, surgical approaches are very costly, may be associated with significant patient morbidity and mortality and may not alter the natural history of the disease. Baropacing also has not gained acceptance. Several problems with electrical carotid sinus nerve stimulation have been reported in the medical literature. These include the invasiveness of the surgical procedure to implant the nerve electrodes, and postoperative pain in the jaw, throat, face and head during stimulation. In addition, it has been noted that high voltages sometimes required for nerve stimulation may damage the carotid sinus nerves. Accordingly, there continues to be a substantial and long felt need for new devices and methods for treating and/or managing high blood pressure, heart failure and their associated cardiovascular and nervous system disorders.
U.S. Pat. No. 6,522,926, signed to the Assignee of the present application, describes a number of systems and methods intended to activate baroreceptors in the carotid sinus and elsewhere in order to induce the baroreflex. Numerous specific approaches are described, including the use of coil electrodes placed over the exterior of the carotid sinus near the carotid bifurcation. While such electrode designs offer substantial promise, there is room for improvement in a number of specific design areas. For example, it would be desirable to provide designs which permit electrode structures to be closely and conformably secured over the exterior of a carotid sinus or other blood vessels so that efficient activation of the underlying baroreceptors can be achieved. It would be further desirable to provide specific electrode structures which can be variably positioned at different locations over the carotid sinus wall or elsewhere. At least some of these objectives will be met by these inventions described hereinbelow.
To address hypertension, heart failure and their associated cardiovascular and nervous system disorders, the present invention provides a number of devices, systems and methods by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably regulated by activating baroreceptors. By selectively and controllably activating baroreceptors, the present invention reduces excessive blood pressure, sympathetic nervous system activation and neurohormonal activation, thereby minimizing their deleterious effects on the heart, vasculature and other organs and tissues.
The present invention provides systems and methods for treating a patient by inducing a baroreceptor signal to effect a change in the baroreflex system (e.g., reduced heart rate, reduced blood pressure, etc.). The baroreceptor signal is activated or otherwise modified by selectively activating baroreceptors. To accomplish this, the system and method of the present invention utilize a baroreceptor activation device positioned near a baroreceptor in the carotid sinus, aortic arch, heart, common carotid arteries, subclavian arteries, and/or brachiocephalic artery. Preferably, the baroreceptor activation device is located in the right and/or left carotid sinus (near the bifurcation of the common carotid artery) and/or the aortic arch. By way of example, not limitation, the present invention is described with reference to the carotid sinus location.
Generally speaking, the baroreceptor activation device may be activated, deactivated or otherwise modulated to activate one or more baroreceptors and induce a baroreceptor signal or a change in the baroreceptor signal to thereby effect a change in the baroreflex system. The baroreceptor activation device may be activated, deactivated, or otherwise modulated continuously, periodically, or episodically. The baroreceptor activation device may comprise a wide variety of devices which utilize electrodes to directly or indirectly activate the baroreceptor. The baroreceptor may be activated directly, or activated indirectly via the adjacent vascular tissue. The baroreceptor activation device will be positioned outside the vascular wall. To maximize therapeutic efficacy, mapping methods may be employed to precisely locate or position the baroreceptor activation device.
The present invention is directed particularly at electrical means and methods to activate baroreceptors, and various electrode designs are provided. The electrode designs may be particularly suitable for connection to the carotid arteries at or near the carotid sinus, and may be designed to minimize extraneous tissue stimulation. While being particularly suitable for use on the carotid arteries at or near the carotid sinus, the electrode structures and assemblies of the present invention will also find use for external placement and securement of electrodes about other arteries, and in some cases veins, having baroreceptor and other electrically activated receptors therein.
In a first aspect of the present invention, a baroreceptor activation device or other electrode useful for a carotid sinus or other blood vessel comprises a base having one or more electrodes connected to the base. The base has a length sufficient to extend around at least a substantial portion of the circumference of a blood vessel, usually an artery, more usually a carotid artery at or near the carotid sinus. By “substantial portion,” it is meant that the base will extend over at least 25% of the vessel circumference, usually at least 50%, more usually at least 66%, and often at least 75% or over the entire circumference. Usually, the base is sufficiently elastic to conform to said circumference or portion thereof when placed therearound. The electrode connected to the base is oriented at least partly in the circumferential direction and is sufficiently stretchable to both conform to the shape of the carotid sinus when the base is conformed thereover and accommodate changes in the shape and size of the sinus as they vary over time with heart pulse and other factors, including body movement which causes the blood vessel circumference to change.
Usually, at least two electrodes will be positioned circumferentially and adjacent to each other on the base. The electrode(s) may extend over the entire length of the base, but in some cases will extend over less than 75% of the circumferential length of the base, often being less than 50% of the circumferential length, and sometimes less than 25% of the circumferential length. Thus, the electrode structures may cover from a small portion up to the entire circumferential length of the carotid artery or other blood vessel. Usually, the circumferential length of the elongate electrodes will cover at least 10 of the circumference of the blood vessel, typically being at least 25%, often at least 50%, 75%, or the entire length. The base will usually have first and second ends, wherein the ends are adapted to be joined, and will have sufficient structural integrity to grasp the carotid sinus.
In a further aspect of the present invention, an extravascular electrode assembly comprises an elastic base and a stretchable electrode. The elastic base is adapted to be conformably attached over the outside of a target blood vessel, such as a carotid artery at or near the carotid sinus, and the stretchable electrode is secured over the elastic base and capable of expanding and contracting together with the base. In this way, the electrode assembly is conformable to the exterior of the carotid sinus or other blood vessel. Preferably, the elastic base is planar, typically comprising an elastomeric sheet. While the sheet may be reinforced, the reinforcement will be arranged so that the sheet remains elastic and stretchable, at least in the circumferential direction, so that the base and electrode assembly may be placed and conformed over the exterior of the blood vessel. Suitable elastomeric sheets may be composed of silicone, latex, and the like.
To assist in mounting the extravascular electrode over the carotid sinus or other blood vessel, the assembly will usually include two or more attachment tabs extending from the elastomeric sheet at locations which allow the tabs to overlap the elastic base and/or be directly attached to the blood vessel wall when the base is wrapped around or otherwise secured over a blood vessel. In this way, the tabs may be fastened to secure the backing over the blood vessel.
Preferred stretchable electrodes comprise elongated coils, where the coils may stretch and shorten in a spring-like manner. In particularly preferred embodiments, the elongated coils will be flattened over at least a portion of their lengths, where the flattened portion is oriented in parallel to the elastic base. The flattened coil provides improved electrical contact when placed against the exterior of the carotid sinus or other blood vessel.
In a further aspect of the present invention, an extravascular electrode assembly comprises a base and an electrode structure. The base is adapted to be attached over the outside of a carotid artery or other blood vessel and has an electrode-carrying surface formed over at least a portion thereof. A plurality of attachment tabs extend away from the electrode-carrying surface, where the tabs are arranged to permit selective ones thereof to be wrapped around a blood vessel while others of the tabs may be selectively removed. The electrode structure on or over the electrode-carrying surface.
In preferred embodiments, the base includes at least one tab which extends longitudinally from the electrode-carrying surface and at least two tabs which extend away from the surface at opposite, transverse angles. In an even more preferred embodiment, the electrode-carrying surface is rectangular, and at least two longitudinally extending tabs extend from adjacent corners of the rectangular surface. The two transversely angled tabs extend at a transverse angle away from the same two corners.
As with prior embodiments, the electrode structure preferably includes one or more stretchable electrodes secured to the electrode-carrying surface. The stretchable electrodes are preferably elongated coils, more preferably being “flattened coils” to enhance electrical contact with the blood vessel to be treated. The base is preferably an elastic base, more preferably being formed from an elastomeric sheet. The phrase “flattened coil,” as used herein, refers to an elongate electrode structure including a plurality of successive turns where the cross-sectional profile is non-circular and which includes at least one generally flat or minimally curved face. Such coils may be formed by physically deforming (flattening) a circular coil, e.g., as shown in
In a still further aspect of the present invention, a method for wrapping an electrode assembly over a blood vessel comprises providing an electrode assembly having an elastic base and one or more stretchable electrodes. The base is conformed over an exterior of the blood vessel, such as a carotid artery, and at least a portion of an electrode is stretched along with the base. Ends of the elastic base are secured together to hold the electrode assembly in place, typically with both the elastic backing and stretchable electrode remaining under at least slight tension to promote conformance to the vessel exterior. The electrode assembly will be located over a target site in the blood vessel, typically a target site having an electrically activated receptor. Advantageously, the electrode structures of the present invention when wrapped under tension will flex and stretch with expansions and contractions of the blood vessel. A presently preferred target site is a baroreceptor, particularly baroreceptors in or near the carotid sinus.
In a still further aspect of the present invention, a method for wrapping an electrode assembly over a blood vessel comprises providing an electrode assembly including a base having an electrode-carrying surface and an electrode structure on the electrode-carrying surface. The base is wrapped over a blood vessel, and some but not all of a plurality of attachment tags on the base are secured over the blood vessel. Usually, the tabs which are not used to secure an electrode assembly will be removed, typically by cutting. Preferred target sites are electrically activated receptors, usually baroreceptors, more usually baroreceptors on the carotid sinus. The use of such electrode assemblies having multiple attachment tabs is particularly beneficial when securing the electrode assembly on a carotid artery near the carotid sinus. By using particular tabs, as described in more detail below, the active electrode area can be positioned at any of a variety of locations on the common, internal, and/or external carotid arteries.
In another aspect, the present invention comprises pressure measuring assemblies including an elastic base adapted to be mounted on the outer wall of a blood vessel under circumferential tension. A strain measurement sensor is positioned on the base to measure strain resulting from circumferential expansion of the vessel due to a blood pressure increase. Usually, the base will wrap about the entire circumference of the vessel, although only a portion of the base need be elastic. Alternatively, a smaller base may be stapled, glued, clipped or otherwise secured over a “patch” of the vessel wall to detect strain variations over the underlying surface. Exemplary sensors include strain gauges and micro machined sensors (MEMS).
In yet another aspect, electrode assemblies according to the present invention comprise a base and at least three parallel elongate electrode structures secured over a surface of the base. The base is attachable to an outside surface of a blood vessel, such as a carotid artery, particularly a carotid artery near the carotid sinus, and has a length sufficient to extend around at least a substantial portion of the circumference of the blood vessel, typically extending around at least 25% of the circumference, usually extending around at least 50% of the circumference, preferably extending at least 66% of the circumference, and often extending around at least 75% of or the entire circumference of the blood vessel. As with prior embodiments, the base will preferably be elastic and composed of any of the materials set forth previously.
The at least three parallel elongate electrode structures will preferably be aligned in the circumferential direction of the base, i.e., the axis or direction of the base which will be aligned circumferentially over the blood vessel when the base is mounted on the blood vessel. The electrode structures will preferably be stretchable, typically being elongate coils, often being flattened elongate coils, as also described previously.
At least an outer pair of the electrode structures will be electrically isolated from an inner electrode structure, and the outer electrode structures will preferably be arranged in a U-pattern in order to surround the inner electrode structure. In this way, the outer pair of electrodes can be connected using a single conductor taken from the base, and the outer electrode structures and inner electrode structure may be connected to separate poles on a power supply in order to operate in the “pseudo” tripolar mode described hereinbelow.
To address low blood pressure and other conditions requiring blood pressure augmentation, the present invention provides electrode designs and methods utilizing such electrodes by which the blood pressure may be selectively and controllably regulated by inhibiting or dampening baroreceptor signals. By selectively and controllably inhibiting or dampening baroreceptor signals, the present invention reduces conditions associated with low blood pressure.
The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
To better understand the present invention, it may be useful to explain some of the basic vascular anatomy associated with the cardiovascular system. Refer to
From the aortic arch 12, oxygenated blood flows into the carotid arteries 18/19 and the subclavian arteries 13/16. From the carotid arteries 18/19, oxygenated blood circulates through the head and cerebral vasculature and oxygen depleted blood returns to the heart 11 by way of the jugular veins, of which only the right internal jugular vein 21 is shown for sake of clarity. From the sub clavian arteries 13/16, oxygenated blood circulates through the upper peripheral vasculature and oxygen depleted blood returns to the heart by way of the subclavian veins, of which only the right subclavian vein 23 is shown, also for sake of clarity. The heart 11 pumps the oxygen depleted blood through the pulmonary system where it is reoxygenated. The re-oxygenated blood returns to the heart 11 which pumps the re-oxygenated blood into the aortic arch as described above, and the cycle repeats.
Within the arterial walls of the aortic arch 12, common carotid arteries 14/15 (near the right carotid sinus 20 and left carotid sinus), subclavian arteries 13/16 and brachiocephalic artery 22 there are baroreceptors 30. For example, as best seen in
Refer now to
Baroreceptor signals are used to activate a number of body systems which collectively may be referred to as the baroreflex system 50. Baroreceptors 30 are connected to the brain 52 via the nervous system 51. Thus, the brain 52 is able to detect changes in blood pressure, which is indicative of cardiac output. If cardiac output is insufficient to meet demand (i.e., the heart 11 is unable to pump sufficient blood), the baroreflex system 50 activates a number of body systems, including the heart 11, kidneys 53, vessels 54, and other organs/tissues. Such activation of the baroreflex system 50 generally corresponds to an increase in neurohormonal activity. Specifically, the baroreflex system 50 initiates a neurohormonal sequence that signals the heart 11 to increase heart rate and increase contraction force in order to increase cardiac output, signals the kidneys 53 to increase blood volume by retaining sodium and water, and signals the vessels 54 to constrict to elevate blood pressure. The cardiac, renal and vascular responses increase blood pressure and cardiac output 55, and thus increase the workload of the heart 11. In a patient with heart failure, this further accelerates myocardial damage and exacerbates the heart failure state.
To address the problems of hypertension, heart failure, other cardiovascular disorders and renal disorders, the present invention basically provides a number of devices, systems and methods by which the baroreflex system 50 is activated to reduce excessive blood pressure, autonomic nervous system activity and neurohormonal activation. In particular, the present invention provides a number of devices, systems and methods by which baroreceptors 30 may be activated, thereby indicating an increase in blood pressure and signaling the brain 52 to reduce the body's blood pressure and level of sympathetic nervous system and neurohormonal activation, and increase parasypathetic nervous system activation, thus having a beneficial effect on the cardiovascular system and other body systems.
With reference to
As mentioned previously, the baroreceptor activation device 70 may comprise a wide variety of devices which utilize electrical means to activate the baroreceptors 30. The baroreceptor activation device 70 of the present invention comprises an electrode structure which directly activates one or more baroreceptors 30 by changing the electrical potential across the baroreceptors 30. It is possible that changing the electrical potential across the tissue surrounding the baroreceptors 30 may cause the surrounding tissue to stretch or otherwise deform, thus mechanically activating the baroreceptors 30, in which case the stretchable and elastic electrode structures of the present invention may provide significant advantages.
All of the specific embodiments of the electrode structures of the present invention are suitable for implantation, and are preferably implanted using a minimally invasive surgical approach. The baroreceptor activation device 70 may be positioned anywhere baroreceptors 30 are present. Such potential implantation sites are numerous, such as the aortic arch 12, in the common carotid arteries 18/19 near the carotid sinus 20, in the subclavian arteries 13/16, in the brachiocephalic artery 22, or in other arterial or venous locations. The electrode structures of the present invention will be implanted such that they are positioned on or over a vascular structure immediately adjacent the baroreceptors 30. Preferably, the electrode structure of the baroreceptor activation device 70 is implanted near the right carotid sinus 20 and/or the left carotid sinus (near the bifurcation of the common carotid artery) and/or the aortic arch 12, where baroreceptors 30 have a significant impact on the baroreflex system 50. For purposes of illustration only, the present invention is described with reference to baroreceptor activation device 70 positioned near the carotid sinus 20.
The optional sensor 80 is operably coupled to the control system 60 by electric sensor cable or lead 82. The sensor 80 may comprise any suitable device that measures or monitors a parameter indicative of the need to modify the activity of the baroreflex system. For example, the sensor 80 may comprise a physiologic transducer or gauge that measures ECG, blood pressure (systolic, diastolic, average or pulse pressure), blood volumetric flow rate, blood flow velocity, blood pH, O2 or CO2 content, mixed venous oxygen saturation (SVO2), vasoactivity, nerve activity, tissue activity, body movement, activity levels, respiration, or composition. Examples of suitable transducers or gauges for the sensor 80 include ECG electrodes, a piezoelectric pressure transducer, an ultrasonic flow velocity transducer, an ultrasonic volumetric flow rate transducer, a thermodilution flow velocity transducer, a capacitive pressure transducer, a membrane pH electrode, an optical detector (SVO2), tissue impedance (electrical), or a strain gauge. Although only one sensor 80 is shown, multiple sensors 80 of the same or different type at the same or different locations may be utilized.
An example of an implantable blood pressure measurement device that may be disposed about a blood vessel is disclosed in U.S. Pat. No. 6,106,477 to Miesel et al., the entire disclosure of which is incorporated herein by reference. An example of a subcutaneous ECG monitor is available from Medtronic under the trade name REVEAL ILR and is disclosed in PCT Publication No. WO 98/02209, the entire disclosure of which is incorporated herein by reference. Other examples are disclosed in U.S. Pat. Nos. 5,987,352 and 5,331,966, the entire disclosures of which are incorporated herein by reference. Examples of devices and methods for measuring absolute blood pressure utilizing an ambient pressure reference are disclosed in U.S. Pat. No. 5,810,735 to Halperin et al., U.S. Pat. No. 5,904,708 to Goedeke, and PCT Publication No. WO 00/16686 to Brockway et al., the entire disclosures of which are incorporated herein by reference. The sensor 80 described herein may take the form of any of these devices or other devices that generally serve the same purpose.
The sensor 80 is preferably positioned in a chamber of the heart 11, or in/on a major artery such as the aortic arch 12, a common carotid artery 14/15, a subclavian artery 13/16 or the brachiocephalic artery 22, such that the parameter of interest may be readily ascertained. The sensor 80 may be disposed inside the body such as in or on an artery, a vein or a nerve (e.g. vagus nerve), or disposed outside the body, depending on the type of transducer or gauge utilized. The sensor 80 may be separate from the baroreceptor activation device 70 or combined therewith. For purposes of illustration only, the sensor 80 is shown positioned on the right subclavian artery 13.
By way of example, the control system 60 includes a control block 61 comprising a processor 63 and a memory 62. Control system 60 is connected to the sensor 80 by way of sensor cable 82. Control system 60 is also connected to the baroreceptor activation device 70 by way of electric control cable 72. Thus, the control system 60 receives a sensor signal from the sensor 80 by way of sensor cable 82, and transmits a control signal to the baroreceptor activation device 70 by way of control cable 72.
The system components 60/70/80 may be directly linked via cables 72/82 or by indirect means such as RF signal transceivers, ultrasonic transceivers or galvanic couplings. Examples of such indirect interconnection devices are disclosed in U.S. Pat. No. 4,987,897 to Funke and U.S. Pat. No. 5,113,859 to Funke, the entire disclosures of which are incorporated herein by reference.
The memory 62 may contain data related to the sensor signal, the control signal, and/or values and commands provided by the input device 64. The memory 62 may also include software containing one or more algorithms defining one or more functions or relationships between the control signal and the sensor signal. The algorithm may dictate activation or deactivation control signals depending on the sensor signal or a mathematical derivative thereof. The algorithm may dictate an activation or deactivation control signal when the sensor signal falls below a lower predetermined threshold value, rises above an upper predetermined threshold value or when the sensor signal indicates a specific physiologic event. The algorithm may dynamically alter the threshold value as determined by the sensor input values.
As mentioned previously, the baroreceptor activation device 70 activates baroreceptors 30 electrically, optionally in combination with mechanical, thermal, chemical, biological or other co-activation. In some instances, the control system 60 includes a driver 66 to provide the desired power mode for the baroreceptor activation device 70. For example, the driver 66 may comprise a power amplifier or the like and the cable 72 may comprise electrical lead(s). In other instances, the driver 66 may not be necessary, particularly if the processor 63 generates a sufficiently strong electrical signal for low level electrical actuation of the baroreceptor activation device 70.
The control system 60 may operate as a closed loop utilizing feedback from the sensor 80, or other sensors, such as heart rate sensors which may be incorporated or the electrode assembly, or as an open loop utilizing reprogramming commands received by input device 64. The closed loop operation of the control system 60 preferably utilizes some feedback from the transducer 80, but may also operate in an open loop mode without feedback. Programming commands received by the input device 64 may directly influence the control signal, the output activation parameters, or may alter the software and related algorithms contained in memory 62. The treating physician and/or patient may provide commands to input device 64. Display 65 may be used to view the sensor signal, control signal and/or the software/data contained in memory 62.
The control signal generated by the control system 60 may be continuous, periodic, alternating, episodic or a combination thereof, as dictated by an algorithm contained in memory 62. Continuous control signals include a constant pulse, a constant train of pulses, a triggered pulse and a triggered train of pulses. Examples of periodic control signals include each of the continuous control signals described above which have a designated start time (e.g., beginning of each period as designated by minutes, hours, or days in combinations of) and a designated duration (e.g., seconds, minutes, hours, or days in combinations of). Examples of alternating control signals include each of the continuous control signals as described above which alternate between the right and left output channels. Examples of episodic control signals include each of the continuous control signals described above which are triggered by an episode (e.g., activation by the physician/patient, an increase/decrease in blood pressure above a certain threshold, heart rate above/below certain levels, etc.).
The stimulus regimen governed by the control system 60 may be selected to promote long term efficacy. It is theorized that uninterrupted or otherwise unchanging activation of the baroreceptors 30 may result in the baroreceptors and/or the baroreflex system becoming less responsive over time, thereby diminishing the long term effectiveness of the therapy. Therefore, the stimulus regimen maybe selected to activate, deactivate or otherwise modulate the baroreceptor activation device 70 in such a way that therapeutic efficacy is maintained preferably for years.
In addition to maintaining therapeutic efficacy over time, the stimulus regimens of the present invention may be selected reduce power requirement/consumption of the system 60. As will be described in more detail hereinafter, the stimulus regimen may dictate that the baroreceptor activation device 70 be initially activated at a relatively higher energy and/or power level, and subsequently activated at a relatively lower energy and/or power level. The first level attains the desired initial therapeutic effect, and the second (lower) level sustains the desired therapeutic effect long term. By reducing the energy and/or power levels after the desired therapeutic effect is initially attained, the energy required or consumed by the activation device 70 is also reduced long term. This may correlate into systems having greater longevity and/or reduced size (due to reductions in the size of the power supply and associated components).
A first general approach for a stimulus regimen which promotes long term efficacy and reduces power requirements/consumption involves generating a control signal to cause the baroreceptor activation device 70 to have a first output level of relatively higher energy and/or power, and subsequently changing the control signal to cause the baroreceptor activation device 70 to have a second output level of relatively lower energy and/or power. The first output level may be selected and maintained for sufficient time to attain the desired initial effect (e.g., reduced heart rate and/or blood pressure), after which the output level may be reduced to the second level for sufficient time to sustain the desired effect for the desired period of time.
For example, if the first output level has a power and/or energy value of X1, the second output level may have a power and/or energy value of X2, wherein X2 is less than X1. In some instances, X2 may be equal to zero, such that the first level is “on” and the second level is “off”. It is recognized that power and energy refer to two different parameters, and in some cases, a change in one of the parameters (power or energy) may not correlate to the same or similar change in the other parameter. In the present invention, it is contemplated that a change in one or both of the parameters may be suitable to obtain the desired result of promoting long term efficacy.
It is also contemplated that more than two levels may be used. Each further level may increase the output energy or power to attain the desired effect, or decrease the output energy or power to retain the desired effect. For example, in some instances, it may be desirable to have further reductions in the output level if the desired effect may be sustained at lower power or energy levels. In other instances, particularly when the desired effect is diminishing or is otherwise not sustained, it may be desirable to increase the output level until the desired effect is reestablished, and subsequently decrease the output level to sustain the effect.
The transition from each level may be a step function (e.g., a single step or a series of steps), a gradual transition over a period of time, or a combination thereof. In addition, the signal levels may be continuous, periodic, alternating, or episodic as discussed previously.
In electrical activation using a non modulated signal, the output (power or energy) level of the baroreceptor activation device 70 may be changed by adjusting the output signal voltage level, current level and/or signal duration. The output signal of the baroreceptor activation device 70 may be, for example, constant current or constant voltage. In electrical activation embodiments using a modulated signal, wherein the output signal comprises, for example, a series of pulses, several pulse characteristics may be changed individually or in combination to change the power or energy level of the output signal. Such pulse characteristics include, but are not limited to: pulse amplitude (PA), pulse frequency (PF), pulse width or duration (PW), pulse waveform (square, triangular, sinusoidal, etc.), pulse polarity (for bipolar electrodes) and pulse phase (monophasic, biphasic).
In electrical activation wherein the output signal comprises a pulse train, several other signal characteristics may be changed in addition to the pulse characteristics described above, as described in copending application Ser. No. 09/964,079, the full disclosure of which is incorporated herein by reference.
Refer now to
In
The carotid sinus 20, and in particular the bulge 21 of the carotid sinus, may contain a relatively high density of baroreceptors 30 (not shown) in the vascular wall. For this reason, it may be desirable to position the electrodes 302 of the activation device 300 on and/or around the sinus bulge 21 to maximize baroreceptor responsiveness and to minimize extraneous tissue stimulation.
It should be understood that the device 300 and electrodes 302 are merely schematic, and only a portion of which may be shown, for purposes of illustrating various positions of the electrodes 302 on and/or around the carotid sinus 20 and the sinus bulge 21. In each of the embodiments described herein, the electrodes 302 may be monopolar, bipolar, or tripolar (anode-cathode-anode or cathode-anode-cathode sets). Specific extravascular electrode designs are described in more detail hereinafter.
In
The plurality of electrode pairs 302 may extend from a point proximal of the sinus 20 or bulge 21, to a point distal of the sinus 20 or bulge 21 to ensure activation of baroreceptors 30 throughout the sinus 20 region. The electrodes 302 may be connected to a single channel or multiple channels as discussed in more detail hereinafter. The plurality of electrode pairs 302 may be selectively activated for purposes of targeting a specific area of the sinus 20 to increase baroreceptor responsiveness, or for purposes of reducing the exposure of tissue areas to activation to maintain baroreceptor responsiveness long term.
In
From the foregoing discussion with reference to
For example, in
Refer now to
Base structure or substrate 306 may comprise a flexible and electrically insulating material suitable for implantation, such as silicone, perhaps reinforced with a flexible material such as polyester fabric. The base 306 may have a length suitable to wrap around all (360.degree.) or a portion (i.e., less than 360.degree.) of the circumference of one or more of the carotid arteries adjacent the carotid sinus 20. The electrodes 302 may extend around a portion (i.e., less than 360.degree. such as 270.degree., 180.degree. or 90.degree.) of the circumference of one or more of the carotid arteries adjacent the carotid sinus 20. To this end, the electrodes 302 may have a length that is less than (e.g., 75%, 50% or 25%) the length of the base 206. The electrodes 302 may be parallel, orthogonal or oblique to the length of the base 306, which is generally orthogonal to the axis of the carotid artery to which it is disposed about. Preferably, the base structure or backing will be elastic (i.e., stretchable), typically being composed of at least in part of silicone, latex, or other elastomer. If such elastic structures are reinforced, the reinforcement should be arranged so that it does not interfere with the ability of the base to stretch and conform to the vascular surface.
The electrodes 302 may comprise round wire, rectangular ribbon or foil formed of an electrically conductive and radiopaque material such as platinum. The base structure 306 substantially encapsulates the electrodes 302, leaving only an exposed area for electrical connection to extravascular carotid sinus tissue. For example, each electrode 302 may be partially recessed in the base 206 and may have one side exposed along all or a portion of its length for electrical connection to carotid tissue. Electrical paths through the carotid tissues may be defined by one or more pairs of the elongate electrodes 302.
In all embodiments described with reference to
An alternative multi-channel electrode design is illustrated in
A variation of the multi-channel pad type electrode design is illustrated in
Another variation of the multi-channel pad electrode design is illustrated in
For example, the control signal may comprise a pulse wave form, wherein each pulse includes a different code. The code for each pulse causes the chip 310 to enable one or more pairs of electrodes, and to disable the remaining electrodes. Thus, the pulse is only transmitted to the enabled electrode pair(s) corresponding to the code sent with that pulse. Each subsequent pulse would have a different code than the preceding pulse, such that the chip 310 enables and disables a different set of electrodes 302 corresponding to the different code. Thus, virtually any number of electrode pairs may be selectively activated using control chip 310, without the need for a separate channel in cable 304 for each electrode 302. By reducing the number of channels in cable 304, the size and cost thereof may be reduced.
Optionally, the IC chip 310 may be connected to feedback sensor 80, taking advantage of the same functions as described with reference to
Refer now to
In this embodiment, the base structure 306 of the activation device 300 may comprise molded tube, a tubular extrusion, or a sheet of material wrapped into a tube shape utilizing a suture flap 308 with sutures 309 as shown. The base structure 306 may be formed of a flexible and biocompatible material such as silicone, which may be reinforced with a flexible material such as polyester fabric available under the trade name DACRON® to form a composite structure. The inside diameter of the base structure 306 may correspond to the outside diameter of the carotid artery at the location of implantation, for example 6 to 8 mm. The wall thickness of the base structure 306 may be very thin to maintain flexibility and a low profile, for example less than 1 mm. If the device 300 is to be disposed about a sinus bulge 21, a correspondingly shaped bulge may be formed into the base structure for added support and assistance in positioning.
The electrodes 302 (shown in phantom) may comprise round wire, rectangular ribbon or foil, formed of an electrically conductive and radiopaque material such as platinum or platinum iridium. The electrodes may be molded into the base structure 306 or adhesively connected to the inside diameter thereof, leaving a portion of the electrode exposed for electrical connection to carotid tissues. The electrodes 302 may encompass less than the entire inside circumference (e.g., 300.degree.) of the base structure 306 to avoid shorting. The electrodes 302 may have any of the shapes and arrangements described previously. For example, as shown in
The support collar 312 may be formed similarly to base structure 306. For example, the support collar may comprise molded tube, a tubular extrusion, or a sheet of material wrapped into a tube shape utilizing a suture flap 315 with sutures 313 as shown. The support collar 312 may be formed of a flexible and biocompatible material such as silicone, which may be reinforced to form a composite structure. The cables 304 are secured to the support collar 312, leaving slack in the cables 304 between the support collar 312 and the activation device 300.
In all embodiments described herein, it may be desirable to secure the activation device to the vascular wall using sutures or other fixation means. For example, sutures 311 may be used to maintain the position of the electrical activation device 300 relative to the carotid anatomy (or other vascular site containing baroreceptors). Such sutures 311 may be connected to base structure 306, and pass through all or a portion of the vascular wall. For example, the sutures 311 may be threaded through the base structure 306, through the adventitia of the vascular wall, and tied. If the base structure 306 comprises a patch or otherwise partially surrounds the carotid anatomy, the corners and/or ends of the base structure may be sutured, with additional sutures evenly distributed therebetween. In order to minimize the propagation of a hole or a tear through the base structure 306, a reinforcement material such as polyester fabric may be embedded in the silicone material. In addition to sutures, other fixation means may be employed such as staples or a biocompatible adhesive, for example.
Refer now to
The ribs 316 of the activation device 300 are sized to fit about the carotid anatomy, such as the internal carotid artery 19 adjacent the carotid sinus 20. Similarly, the ribs 316 of the support collar 312 may be sized to fit about the carotid anatomy, such as the common carotid artery 14 proximal of the carotid sinus 20. The ribs 316 may be separated, placed on a carotid artery, and closed thereabout to secure the device 300 to the carotid anatomy.
Each of the ribs 316 of the device 300 includes an electrode 302 on the inside surface thereof for electrical connection to carotid tissues. The ribs 316 provide insulating material around the electrodes 302, leaving only an inside portion exposed to the vascular wall. The electrodes 302 are coupled to the multi-channel cable 304 through spine 317. Spine 317 also acts as a tether to ribs 316 of the support collar 312, which do not include electrodes since their function is to provide support. The multi-channel electrode 302 functions discussed with reference to
The ends of the ribs 316 may be connected (e.g., sutured) after being disposed about a carotid artery, or may remain open as shown. If the ends remain open, the ribs 316 may be formed of a relatively stiff material to ensure a mechanical lock around the carotid artery. For example, the ribs 316 may be formed of polyethylene, polypropylene, PTFE, or other similar insulating and biocompatible material. Alternatively, the ribs 316 may be formed of a metal such as stainless steel or a nickel titanium alloy, as long as the metallic material was electrically isolated from the electrodes 302. As a further alternative, the ribs 316 may comprise an insulating and biocompatible polymeric material with the structural integrity provided by metallic (e.g., stainless steel, nickel titanium alloy, etc.) reinforcement. In this latter alternative, the electrodes 302 may comprise the metallic reinforcement.
Refer now to
The electrodes 302 are connected to a modified bipolar endocardial pacing lead, available under the trade name CONIFIX from Innomedica (now BIOMEC Cardiovascular, Inc.), model number 501112. The proximal end of the cable 304 is connected to the control system 60 or driver 66 as described previously. The pacing lead is modified by removing the pacing electrode to form the cable body 304. The MP35 wires are extracted from the distal end thereof to form two coils 318 positioned side by side having a diameter of about 0.020 inches. The coils 318 are then attached to the electrodes utilizing 316 type stainless steel crimp terminals laser welded to one end of the platinum electrodes 302. The distal end of the cable 304 and the connection between the coils 318 and the ends of the electrodes 302 are encapsulated by silicone.
The cable 304 illustrated in
In this alternative embodiment, the cable body 304 may comprise two or more conductive wires 304a arranged coaxially or collinearly as shown. Each conductive wire 304a may comprise a multifilament structure of suitable conductive material such as stainless steel or MP35N. An insulating material may surround the wire conductors 304a individually and/or collectively. For purposes of illustration only, a pair of electrically conductive wires 304a having an insulating material surrounding each wire 304a individually is shown. The insulated wires 304a may be connected by a spacer 304b comprising, for example, an insulating material. An additional jacket of suitable insulating material may surround each of the conductors 304a. The insulating jacket may be formed to have the same curvilinear shape of the insulated wires 304a to help maintain the shape of the cable body 304 during implantation.
If a sinusoidal configuration is chosen for the curvilinear shape, the amplitude (A) may range from 1 mm to 10 mm, and preferably ranges from 2 mm to 3 mm. The wavelength (WL) of the sinusoid may range from 2 mm to 20 mm, and preferably ranges from 4 mm to 10 mm. The curvilinear or sinusoidal shape may be formed by a heat setting procedure utilizing a fixture which holds the cable 304 in the desired shape while the cable is exposed to heat. Sufficient heat is used to heat set the conductive wires 304a and/or the surrounding insulating material. After cooling, the cable 304 may be removed from the fixture, and the cable 304 retains the desired shape.
Refer now to
Alternatively, the transducer 750 may be adhesively connected to the wall of the artery 14 using a biologically compatible adhesive such as cyanoacrylate as shown in
Refer now to
As seen in
Each turn of the coil in the contact area of the electrodes 702/704 is exposed from the flexible support 706 and any adhesive to form a conductive path to the artery wall. The exposed electrodes 702/704 may have a length (e.g., 0.236 inches) sufficient to extend around at least a portion of the carotid sinus, for example. The electrode cuff 700 is assembled flat with the contact surfaces of the coil electrodes 702/704 tangent to the inside plane of the flexible support 706. When the electrode cuff 700 is wrapped around the artery, the inside contact surfaces of the coiled electrodes 702/704 are naturally forced to extend slightly above the adjacent surface of the flexible support, thereby improving contact to the artery wall.
The ratio of the diameter of the coiled electrodes 702/704 to the wire diameter is preferably large enough to allow the coil to bend and elongate without significant bending stress or torsional stress in the wire. Flexibility is a significant advantage of this design which allows the electrode cuff 700 to conform to the shape of the carotid artery and sinus, and permits expansion and contraction of the artery or sinus without encountering significant stress or fatigue. In particular, the flexible electrode cuff 700 may be wrapped around and stretched to conform to the shape of the carotid sinus and artery during implantation. This may be achieved without collapsing or distorting the shape of the artery and carotid sinus due to the compliance of the electrode cuff 700. The flexible support 706 is able to flex and stretch with the conductor coils 702/704 because of the absence of fabric reinforcement in the electrode contact portion of the cuff 700. By conforming to the artery shape, and by the edge of the flexible support 706 sealing against the artery wall, the amount of stray electrical field and extraneous stimulation will likely be reduced.
The pitch of the coil electrodes 702/704 may be greater than the wire diameter in order to provide a space between each turn of the wire to thereby permit bending without necessarily requiring axial elongation thereof. For example, the pitch of the contact coils 702/704 may be 0.004 inches per turn with a 0.002 inch diameter wire, which allows for a 0.002 inch space between the wires in each turn. The inside of the coil may be filled with a flexible adhesive material such as silicone adhesive which may fill the spaces between adjacent wire turns. By filling the small spaces between the adjacent coil turns, the chance of pinching tissue between coil turns is minimized thereby avoiding abrasion to the artery wall. Thus, the embedded coil electrodes 702/704 are mechanically captured and chemically bonded into the flexible support 706. In the unlikely event that a coil electrode 702/704 comes loose from the support 706, the diameter of the coil is large enough to be atraumatic to the artery wall. Preferably, the centerline of the coil electrodes 702/704 lie near the neutral axis of electrode cuff structure 700 and the flexible support 706 comprises a material with isotropic elasticity such as silicone in order to minimize the shear forces on the adhesive bonds between the coil electrodes 702/704 and the support 706.
The electrode coils 702/704 are connected to corresponding conductive coils 712/714, respectively, in an elongate lead 710 which is connected to the control system 60. Anchoring wings 718 may be provided on the lead 710 to tether the lead 710 to adjacent tissue and minimize the effects or relative movement between the lead 710 and the electrode cuff 700. As seen in
The conductive material of the electrodes 702/704 may be a metal as described above or a conductive polymer such as a silicone material filled with metallic particles such as Pt particles. In this latter embodiment, the polymeric electrodes may be integrally formed with the flexible support 706 with the electrode contacts comprising raised areas on the inside surface of the flexible support 706 electrically coupled to the lead 710 by wires or wire coils. The use of polymeric electrodes may be applied to other electrode design embodiments described elsewhere herein.
Reinforcement patches 708 such as DACRON® fabric may be selectively incorporated into the flexible support 706. For example, reinforcement patches 708 may be incorporated into the ends or other areas of the flexible support 706 to accommodate suture anchors. The reinforcement patches 708 provide points where the electrode cuff 700 may be sutured to the vessel wall and may also provide tissue in growth to further anchor the device 700 to the exterior of the vessel wall. For example, the fabric reinforcement patches 708 may extend beyond the edge of the flexible support 706 so that tissue in growth may help anchor the electrode assembly or cuff 700 to the vessel wall and may reduce reliance on the sutures to retain the electrode assembly 700 in place. As a substitute for or in addition to the sutures and tissue in growth, bioadhesives such as cyanoacrylate may be employed to secure the device 700 to the vessel wall. In addition, an adhesive incorporating conductive particles such as Pt coated micro spheres may be applied to the exposed inside surfaces of the electrodes 702/704 to enhance electrical conduction to the tissue and possibly limit conduction along one axis to limit extraneous tissue stimulation.
The reinforcement patches 708 may also be incorporated into the flexible support 706 for strain relief purposes and to help retain the coils 702/704 to the support 706 where the leads 710 attach to the electrode assembly 700 as well as where the outer coil 702 loops back around the inner coil 704. Preferably, the patches 708 are selectively incorporated into the flexible support 706 to permit expansion and contraction of the device 700, particularly in the area of the electrodes 702/704. In particular, the flexible support 706 is only fabric reinforced in selected areas thereby maintaining the ability of the electrode cuff 700 to stretch.
Referring now to
Referring now to
The geometry of the electrode assembly 900, and in particular the geometry of the base 902, is selected to permit a number of different attachment modes to the blood vessel. In particular, the geometry of the assembly 902 of
A number of reinforcement regions 910 (910a, 910b, 910c, 910d, and 910e) are attached to different locations on the base 902 to permit suturing, clipping, stapling, or other fastening of the attachment tabs 906 to each other and/or the electrode-carrying surface 904 of the base 902. In the preferred embodiment intended for attachment at or around the carotid sinus, a first reinforcement strip 910a is provided over an end of the base 902 opposite to the end which carries the attachment tabs. Pairs of reinforcement strips 910b and 910c are provided on each of the axially aligned attachment tabs 906a and 906b, while similar pairs of reinforcement strips 910d and 910e are provided on each of the transversely angled attachment tabs 906c and 906d. In the illustrated embodiment, all attachment tabs will be provided on one side of the base, preferably emanating from adjacent corners of the rectangular electrode-carrying surface 904.
The structure of electrode assembly 900 permits the surgeon to implant the electrode assembly so that the electrodes 920 (which are preferably stretchable, flat-coil electrodes as described in detail above), are located at a preferred location relative to the target baroreceptors. The preferred location may be determined, for example, as described in copending application Ser. No. 09/963,991, filed on Sep. 26, 2001, the full disclosure of which incorporated herein by reference.
Once the preferred location for the electrodes 920 of the electrode assembly 900 is determined, the surgeon may position the base 902 so that the electrodes 920 are located appropriately relative to the underlying baroreceptors. Thus, the electrodes 920 may be positioned over the common carotid artery CC as shown in
In other cases, the bulge of the carotid sinus and the baroreceptors may be located differently with respect to the carotid bifurcation. For example, as shown in
Referring to
In most activation device embodiments described herein, it may be desirable to incorporate anti-inflammatory agents (e.g., steroid eluting electrodes) such as described in U.S. Pat. No. 4,711,251 to Stokes, U.S. Pat. No. 5,522,874 to Gates and U.S. Pat. No. 4,972,848 to Di Domenico et al., the entire disclosures of which are incorporated herein by reference. Such agents reduce tissue inflammation at the chronic interface between the device (e.g., electrodes) and the vascular wall tissue, to thereby increase the efficiency of stimulus transfer, reduce power consumption, and maintain activation efficiency, for example.
Those skilled in the art will recognize that the present invention may be manifested in a variety of forms other than the specific embodiments described and contemplated herein. Accordingly, departures in form and detail may be made without departing from the scope and spirit of the present invention as described in the appended claims.
This application is a continuation of U.S. patent application Ser. No. 10/402,911, filed on Mar. 27, 2003, which (1) is a continuation-in-part of U.S. patent application Ser. No. 09/963,777, filed on Sep. 26, 2001, which is a continuation-in-part of U.S. patent application Ser. No. 09/671,850, filed on Sep. 27, 2000, now issued as U.S. Pat. No. 6,522,926; and (ii) claims the benefit of U.S. Provisional Patent Application No. 60/368,222, filed on Mar. 27, 2002, the disclosures of each of the above being hereby incorporated by reference in their entirety. The parent application for this application has incorporated by reference the disclosures of the following U.S. patent application Ser. No. 09/964,079, filed on Sep. 26, 2001, now issued as U.S. Pat. No. 6,985,774, and U.S. patent application Ser. No. 09/963,991, filed on Sep. 26, 2001, now issued as U.S. Pat. No. 6,850,801, now issued as U.S. Pat. No. 6,850,801, the disclosures of which are also effectively incorporated by reference herein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3309924 | Kolin | Mar 1967 | A |
| 3421511 | Wingrove et al. | Jan 1969 | A |
| 3522811 | Schwartz et al. | Aug 1970 | A |
| 3593718 | Krasner et al. | Jul 1971 | A |
| 3645267 | Hagfors | Feb 1972 | A |
| 3650277 | Sjostrand et al. | Mar 1972 | A |
| 3835864 | Rasor et al. | Sep 1974 | A |
| 3870051 | Brindley | Mar 1975 | A |
| 3943936 | Rasor et al. | Mar 1976 | A |
| 4014318 | Dockum et al. | Mar 1977 | A |
| RE30366 | Rasor et al. | Aug 1980 | E |
| 4256094 | Kapp et al. | Mar 1981 | A |
| 4323073 | Ferris | Apr 1982 | A |
| 4331157 | Keller, Jr. et al. | May 1982 | A |
| 4481953 | Gold et al. | Nov 1984 | A |
| 4525074 | Murakami | Jun 1985 | A |
| 4531943 | Van Tassel et al. | Jul 1985 | A |
| 4551862 | Haber | Nov 1985 | A |
| 4573481 | Bullara | Mar 1986 | A |
| 4586501 | Claracq | May 1986 | A |
| 4590946 | Loeb et al. | May 1986 | A |
| 4628942 | Sweeney et al. | Dec 1986 | A |
| 4640286 | Thomson | Feb 1987 | A |
| 4641664 | Botvidsson | Feb 1987 | A |
| 4664120 | Hess | May 1987 | A |
| 4682583 | Burton et al. | Jul 1987 | A |
| 4702254 | Zabara | Oct 1987 | A |
| 4709690 | Haber | Dec 1987 | A |
| 4711251 | Stokes | Dec 1987 | A |
| 4719921 | Chirife | Jan 1988 | A |
| 4739762 | Palmaz | Apr 1988 | A |
| 4762130 | Fogarty et al. | Aug 1988 | A |
| 4762820 | Gavras | Aug 1988 | A |
| 4770177 | Schroeppel | Sep 1988 | A |
| 4791931 | Slate | Dec 1988 | A |
| 4800882 | Gianturco | Jan 1989 | A |
| 4803988 | Thomson | Feb 1989 | A |
| 4813418 | Harris | Mar 1989 | A |
| 4819662 | Heil, Jr. et al. | Apr 1989 | A |
| 4825871 | Cansell | May 1989 | A |
| 4828544 | Lane et al. | May 1989 | A |
| 4830003 | Wolff et al. | May 1989 | A |
| 4832038 | Arai et al. | May 1989 | A |
| 4860751 | Callaghan | Aug 1989 | A |
| 4862361 | Gordon et al. | Aug 1989 | A |
| 4867164 | Zabara | Sep 1989 | A |
| 4881939 | Newman | Nov 1989 | A |
| 4886062 | Wiktor | Dec 1989 | A |
| 4887608 | Mohl et al. | Dec 1989 | A |
| 4917092 | Todd et al. | Apr 1990 | A |
| 4930517 | Cohen et al. | Jun 1990 | A |
| 4934368 | Lynch | Jun 1990 | A |
| 4940065 | Tanagho et al. | Jul 1990 | A |
| 4960129 | dePaola et al. | Oct 1990 | A |
| 4960133 | Hewson | Oct 1990 | A |
| 4967159 | Manes | Oct 1990 | A |
| 4969458 | Wiktor | Nov 1990 | A |
| 4972848 | Di Domenico et al. | Nov 1990 | A |
| 4987897 | Funke | Jan 1991 | A |
| 5010893 | Sholder | Apr 1991 | A |
| 5025807 | Zabara | Jun 1991 | A |
| 5031621 | Grandjean et al. | Jul 1991 | A |
| 5040533 | Fearnot | Aug 1991 | A |
| 5078736 | Behl | Jan 1992 | A |
| 5086787 | Grandjean et al. | Feb 1992 | A |
| 5092332 | Lee et al. | Mar 1992 | A |
| 5111815 | Mower | May 1992 | A |
| 5113859 | Funke | May 1992 | A |
| 5113869 | Nappholz et al. | May 1992 | A |
| 5117826 | Bartelt et al. | Jun 1992 | A |
| 5134997 | Bennett et al. | Aug 1992 | A |
| 5144960 | Mehra et al. | Sep 1992 | A |
| 5154170 | Bennett et al. | Oct 1992 | A |
| 5154182 | Moaddeb | Oct 1992 | A |
| 5158078 | Bennett et al. | Oct 1992 | A |
| 5170802 | Mehra | Dec 1992 | A |
| 5181911 | Shturman | Jan 1993 | A |
| 5199428 | Obel et al. | Apr 1993 | A |
| 5203326 | Collins | Apr 1993 | A |
| 5215089 | Baker, Jr. | Jun 1993 | A |
| 5222971 | Willard et al. | Jun 1993 | A |
| 5224491 | Mehra | Jul 1993 | A |
| 5243980 | Mehra | Sep 1993 | A |
| 5259394 | Bens | Nov 1993 | A |
| 5265608 | Lee et al. | Nov 1993 | A |
| 5269303 | Wernicket et al. | Dec 1993 | A |
| 5282468 | Klepinski | Feb 1994 | A |
| 5282844 | Stokes et al. | Feb 1994 | A |
| 5295959 | Gurbel et al. | Mar 1994 | A |
| 5299569 | Wernicke et al. | Apr 1994 | A |
| 5304206 | Baker, Jr. et al. | Apr 1994 | A |
| 5314453 | Jeutter | May 1994 | A |
| 5318592 | Schaldach | Jun 1994 | A |
| 5324310 | Greeninger et al. | Jun 1994 | A |
| 5324325 | Moaddeb | Jun 1994 | A |
| 5325870 | Kroll et al. | Jul 1994 | A |
| 5330507 | Schwartz | Jul 1994 | A |
| 5330515 | Rutecki et al. | Jul 1994 | A |
| 5331966 | Bennett et al. | Jul 1994 | A |
| 5335657 | Terry et al. | Aug 1994 | A |
| 5351394 | Weinberg | Oct 1994 | A |
| 5358514 | Schulman et al. | Oct 1994 | A |
| 5387234 | Hirschberg | Feb 1995 | A |
| 5408744 | Gates | Apr 1995 | A |
| 5411535 | Fujii et al. | May 1995 | A |
| 5411540 | Edell et al. | May 1995 | A |
| 5431171 | Harrison et al. | Jul 1995 | A |
| 5437285 | Verrier et al. | Aug 1995 | A |
| 5458626 | Krause | Oct 1995 | A |
| 5507784 | Hill et al. | Apr 1996 | A |
| 5509888 | Miller | Apr 1996 | A |
| 5522854 | Ideker et al. | Jun 1996 | A |
| 5522874 | Gates | Jun 1996 | A |
| 5529067 | Larsen et al. | Jun 1996 | A |
| 5531766 | Kroll et al. | Jul 1996 | A |
| 5531778 | Maschino et al. | Jul 1996 | A |
| 5531779 | Dahl et al. | Jul 1996 | A |
| 5535752 | Halperin et al. | Jul 1996 | A |
| 5540734 | Zabara | Jul 1996 | A |
| 5540735 | Wingrove | Jul 1996 | A |
| 5545132 | Fagan et al. | Aug 1996 | A |
| 5545202 | Dahl et al. | Aug 1996 | A |
| 5551953 | Lattin et al. | Sep 1996 | A |
| 5571150 | Wernicke et al. | Nov 1996 | A |
| 5575809 | Sasaki | Nov 1996 | A |
| 5578061 | Stroetmann et al. | Nov 1996 | A |
| 5593431 | Sheldon | Jan 1997 | A |
| 5634878 | Grundei et al. | Jun 1997 | A |
| 5643330 | Holsheimer et al. | Jul 1997 | A |
| 5645570 | Corbucci | Jul 1997 | A |
| 5651378 | Matheny et al. | Jul 1997 | A |
| 5680590 | Parti | Oct 1997 | A |
| 5683430 | Markowitz et al. | Nov 1997 | A |
| 5690681 | Geddes et al. | Nov 1997 | A |
| 5692882 | Bozeman, Jr. et al. | Dec 1997 | A |
| 5694939 | Cowings | Dec 1997 | A |
| 5695468 | Lafontaine et al. | Dec 1997 | A |
| 5700282 | Zabara | Dec 1997 | A |
| 5707400 | Terry, Jr. et al. | Jan 1998 | A |
| 5715837 | Chen | Feb 1998 | A |
| 5725471 | Davey et al. | Mar 1998 | A |
| 5725563 | Klotz | Mar 1998 | A |
| 5727558 | Hakki et al. | Mar 1998 | A |
| 5741316 | Chen et al. | Apr 1998 | A |
| 5766236 | Detty et al. | Jun 1998 | A |
| 5766527 | Schildgen et al. | Jun 1998 | A |
| 5775331 | Raymond et al. | Jul 1998 | A |
| 5776178 | Pohndorf et al. | Jul 1998 | A |
| 5782891 | Hassler et al. | Jul 1998 | A |
| 5800464 | Kieval | Sep 1998 | A |
| 5807258 | Cimochowski et al. | Sep 1998 | A |
| 5810735 | Halperin et al. | Sep 1998 | A |
| 5814079 | Kieval | Sep 1998 | A |
| 5814089 | Stokes et al. | Sep 1998 | A |
| 5824021 | Rise | Oct 1998 | A |
| 5853652 | Schildgen et al. | Dec 1998 | A |
| 5861012 | Stroebel | Jan 1999 | A |
| 5861015 | Benja-Athon | Jan 1999 | A |
| 5876422 | van Groeningen | Mar 1999 | A |
| 5891181 | Zhu | Apr 1999 | A |
| 5895416 | Barreras, Sr. et al. | Apr 1999 | A |
| 5904708 | Goedeke | May 1999 | A |
| 5913876 | Taylor et al. | Jun 1999 | A |
| 5916239 | Geddes et al. | Jun 1999 | A |
| 5919220 | Stieglitz et al. | Jul 1999 | A |
| 5928272 | Adkins et al. | Jul 1999 | A |
| 5938596 | Woloszki et al. | Aug 1999 | A |
| 5954761 | Machek et al. | Sep 1999 | A |
| 5967986 | Cimochowski et al. | Oct 1999 | A |
| 5967989 | Cimochowski et al. | Oct 1999 | A |
| 5987352 | Klein et al. | Nov 1999 | A |
| 5987746 | Williams | Nov 1999 | A |
| 5989230 | Frassica | Nov 1999 | A |
| 5991667 | Feith | Nov 1999 | A |
| 6006134 | Hill et al. | Dec 1999 | A |
| 6016449 | Fischell et al. | Jan 2000 | A |
| 6023642 | Shealy et al. | Feb 2000 | A |
| 6050952 | Hakki et al. | Apr 2000 | A |
| 6052623 | Fenner et al. | Apr 2000 | A |
| 6058331 | King | May 2000 | A |
| 6061596 | Richmond et al. | May 2000 | A |
| 6073048 | Kieval et al. | Jun 2000 | A |
| 6077227 | Miesel et al. | Jun 2000 | A |
| 6077298 | Tu et al. | Jun 2000 | A |
| 6104956 | Naritoku et al. | Aug 2000 | A |
| 6106477 | Miesel et al. | Aug 2000 | A |
| 6110098 | Renirie et al. | Aug 2000 | A |
| 6115628 | Stadier et al. | Sep 2000 | A |
| 6115630 | Stadier et al. | Sep 2000 | A |
| 6128526 | Stadier et al. | Oct 2000 | A |
| 6141588 | Cox et al. | Oct 2000 | A |
| 6141590 | Renirie et al. | Oct 2000 | A |
| 6161029 | Spreigl et al. | Dec 2000 | A |
| 6161047 | King et al. | Dec 2000 | A |
| 6178349 | Kieval | Jan 2001 | B1 |
| 6178352 | Gruzdowich et al. | Jan 2001 | B1 |
| 6193996 | Effing et al. | Feb 2001 | B1 |
| 6205359 | Boveja | Mar 2001 | B1 |
| 6206914 | Soykan | Mar 2001 | B1 |
| 6208894 | Schulman et al. | Mar 2001 | B1 |
| 6231516 | Keilman et al. | May 2001 | B1 |
| 6253110 | Brabec et al. | Jun 2001 | B1 |
| 6255296 | Daniels | Jul 2001 | B1 |
| 6266564 | Hill et al. | Jul 2001 | B1 |
| 6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
| 6292703 | Meier et al. | Sep 2001 | B1 |
| 6324421 | Stadier et al. | Nov 2001 | B1 |
| 6341236 | Osorio et al. | Jan 2002 | B1 |
| 6371922 | Baumann et al. | Apr 2002 | B1 |
| 6393324 | Gruzdowich et al. | May 2002 | B2 |
| 6397109 | Cammilli et al. | May 2002 | B1 |
| 6401129 | Lenander | Jun 2002 | B1 |
| 6415183 | Scheiner et al. | Jul 2002 | B1 |
| 6438409 | Malik et al. | Aug 2002 | B1 |
| 6438428 | Axelgaard et al. | Aug 2002 | B1 |
| 6442413 | Silver | Aug 2002 | B1 |
| 6442435 | King et al. | Aug 2002 | B2 |
| 6445953 | Bulkes et al. | Sep 2002 | B1 |
| 6473644 | Terry et al. | Oct 2002 | B1 |
| 6522926 | Kieval et al. | Feb 2003 | B1 |
| 6564101 | Zikria | May 2003 | B1 |
| 6564102 | Boveja | May 2003 | B1 |
| 6584362 | Scheiner et al. | Jun 2003 | B1 |
| 6600956 | Maschino | Jul 2003 | B2 |
| 6611713 | Schauerte | Aug 2003 | B2 |
| 6622041 | Terry et al. | Sep 2003 | B2 |
| 6666826 | Salo et al. | Dec 2003 | B2 |
| 6668191 | Boveja | Dec 2003 | B1 |
| 6669645 | Narimatsu et al. | Dec 2003 | B2 |
| 6671556 | Osorio et al. | Dec 2003 | B2 |
| 6701176 | Halperin et al. | Mar 2004 | B1 |
| 6701186 | Spinelli et al. | Mar 2004 | B2 |
| 6704598 | Ding et al. | Mar 2004 | B2 |
| 6748272 | Carlson et al. | Jun 2004 | B2 |
| 6766189 | Yu et al. | Jul 2004 | B2 |
| 6768923 | Ding et al. | Jul 2004 | B2 |
| 6779257 | Kiepen et al. | Aug 2004 | B2 |
| 6826428 | Chen et al. | Nov 2004 | B1 |
| 6850801 | Kieval et al. | Feb 2005 | B2 |
| 6859667 | Goode | Feb 2005 | B2 |
| 6876881 | Baumann et al. | Apr 2005 | B2 |
| 6894204 | Dunshee | May 2005 | B2 |
| 6907285 | Denker et al. | Jun 2005 | B2 |
| 6922585 | Zhou et al. | Jul 2005 | B2 |
| 6935344 | Aboul-Hosn | Aug 2005 | B1 |
| 6937896 | Kroll | Aug 2005 | B1 |
| 6942622 | Turcott | Sep 2005 | B1 |
| 6942686 | Barbut et al. | Sep 2005 | B1 |
| 6985774 | Kieval et al. | Jan 2006 | B2 |
| 7010337 | Furnary et al. | Mar 2006 | B2 |
| 7092755 | Florio | Aug 2006 | B2 |
| 7123961 | Kroll et al. | Oct 2006 | B1 |
| 7139607 | Shelchuk | Nov 2006 | B1 |
| 7146226 | Lau et al. | Dec 2006 | B2 |
| 7155284 | Whitehurst et al. | Dec 2006 | B1 |
| 7158832 | Kieval et al. | Jan 2007 | B2 |
| 7192403 | Russell | Mar 2007 | B2 |
| 7194313 | Libbus | Mar 2007 | B2 |
| 7225025 | Goode | May 2007 | B2 |
| 7228179 | campen et al. | Jun 2007 | B2 |
| 7231248 | Kramer et al. | Jun 2007 | B2 |
| 7236821 | Cates et al. | Jun 2007 | B2 |
| 7236861 | Paradis et al. | Jun 2007 | B2 |
| 7286878 | Stypulkowski | Oct 2007 | B2 |
| 7321793 | Ben Ezra et al. | Jan 2008 | B2 |
| 20010003799 | Boveja | Jun 2001 | A1 |
| 20010020177 | Gruzdowich et al. | Sep 2001 | A1 |
| 20010023367 | King et al. | Sep 2001 | A1 |
| 20020005982 | Borlinghaus | Jan 2002 | A1 |
| 20020016548 | Stadier et al. | Feb 2002 | A1 |
| 20020026228 | Schaurte | Feb 2002 | A1 |
| 20020058877 | Baumann et al. | May 2002 | A1 |
| 20020068897 | Jenkins et al. | Jun 2002 | A1 |
| 20020072776 | Osorio et al. | Jun 2002 | A1 |
| 20020072782 | Osorio et al. | Jun 2002 | A1 |
| 20020103516 | Patwardhan et al. | Aug 2002 | A1 |
| 20020107553 | Hill et al. | Aug 2002 | A1 |
| 20020128700 | Cross, Jr. | Sep 2002 | A1 |
| 20020151051 | Li | Oct 2002 | A1 |
| 20020165586 | Hill et al. | Nov 2002 | A1 |
| 20020183791 | Denker et al. | Dec 2002 | A1 |
| 20030040785 | Maschino et al. | Feb 2003 | A1 |
| 20030050670 | Spinelli et al. | Mar 2003 | A1 |
| 20030060848 | Kieval et al. | Mar 2003 | A1 |
| 20030060857 | Perrson et al. | Mar 2003 | A1 |
| 20030060858 | Kieval et al. | Mar 2003 | A1 |
| 20030078623 | Weinberg et al. | Apr 2003 | A1 |
| 20030093130 | Stypulkowski | May 2003 | A1 |
| 20030100924 | Foreman et al. | May 2003 | A1 |
| 20030149450 | Mayberg | Aug 2003 | A1 |
| 20030212440 | Boveha et al. | Nov 2003 | A1 |
| 20030229380 | Adams et al. | Dec 2003 | A1 |
| 20040010303 | Bolea et al. | Jan 2004 | A1 |
| 20040019364 | Kieval et al. | Jan 2004 | A1 |
| 20040034394 | Woods et al. | Feb 2004 | A1 |
| 20040054292 | Sun et al. | Mar 2004 | A1 |
| 20040062852 | Schroeder et al. | Apr 2004 | A1 |
| 20040064172 | McVenes et al. | Apr 2004 | A1 |
| 20040102818 | Hakky et al. | May 2004 | A1 |
| 20040186523 | Florio | Sep 2004 | A1 |
| 20040193231 | David et al. | Sep 2004 | A1 |
| 20040199210 | Shelchuk | Oct 2004 | A1 |
| 20040210122 | Sieburg | Oct 2004 | A1 |
| 20040210271 | Campen et al. | Oct 2004 | A1 |
| 20040215263 | Virag et al. | Oct 2004 | A1 |
| 20040249416 | Yun et al. | Dec 2004 | A1 |
| 20040249417 | Ransbury et al. | Dec 2004 | A1 |
| 20040254616 | Rossing et al. | Dec 2004 | A1 |
| 20050010263 | Schaurte | Jan 2005 | A1 |
| 20050021092 | Yun et al. | Jan 2005 | A1 |
| 20050065553 | Ben-Ezra et al. | Mar 2005 | A1 |
| 20050143779 | Libbus | Jun 2005 | A1 |
| 20050143785 | Libbus | Jun 2005 | A1 |
| 20050149126 | Libbus | Jul 2005 | A1 |
| 20050149127 | Libbus | Jul 2005 | A1 |
| 20050149128 | Heil et al. | Jul 2005 | A1 |
| 20050149129 | Libbus et al. | Jul 2005 | A1 |
| 20050149130 | Libbus | Jul 2005 | A1 |
| 20050149131 | Libbus et al. | Jul 2005 | A1 |
| 20050149132 | Libbus | Jul 2005 | A1 |
| 20050149133 | Libbus et al. | Jul 2005 | A1 |
| 20050149143 | Libbus et al. | Jul 2005 | A1 |
| 20050149155 | Scheiner et al. | Jul 2005 | A1 |
| 20050149156 | Libbus et al. | Jul 2005 | A1 |
| 20050154418 | Kieval et al. | Jul 2005 | A1 |
| 20050182468 | Hunter et al. | Aug 2005 | A1 |
| 20050197675 | David et al. | Sep 2005 | A1 |
| 20060004417 | Rossing et al. | Jan 2006 | A1 |
| 20060089678 | Shalev | Apr 2006 | A1 |
| 20060100668 | Ben-David et al. | May 2006 | A1 |
| 20060111745 | Foreman et al. | May 2006 | A1 |
| 20060206155 | Ben-David et al. | Sep 2006 | A1 |
| 20060224222 | Bradely et al. | Oct 2006 | A1 |
| 20070021790 | Kieval et al. | Jan 2007 | A1 |
| 20070021794 | Kieval et al. | Jan 2007 | A1 |
| 20070021796 | Kieval et al. | Jan 2007 | A1 |
| 20070021797 | Kieval et al. | Jan 2007 | A1 |
| 20070021798 | Kieval et al. | Jan 2007 | A1 |
| 20070021799 | Kieval et al. | Jan 2007 | A1 |
| 20070038255 | Kieval et al. | Feb 2007 | A1 |
| 20070038259 | Kieval et al. | Feb 2007 | A1 |
| 20070038260 | Kieval et al. | Feb 2007 | A1 |
| 20070038261 | Kieval et al. | Feb 2007 | A1 |
| 20070038262 | Kieval et al. | Feb 2007 | A1 |
| 20070038278 | Zarembo | Feb 2007 | A1 |
| 20070106340 | Bolea et al. | May 2007 | A1 |
| 20070161912 | Zhang et al. | Jul 2007 | A1 |
| 20070167984 | Kieval et al. | Jul 2007 | A1 |
| 20070179543 | Ben-David et al. | Aug 2007 | A1 |
| 20070185542 | Bolea et al. | Aug 2007 | A1 |
| 20070191895 | Foreman et al. | Aug 2007 | A1 |
| 20070191904 | Libbus et al. | Aug 2007 | A1 |
| 20080049376 | Stevenson et al. | Feb 2008 | A1 |
| 20080167694 | Bolea et al. | Jul 2008 | A1 |
| 20080171923 | Bolea et al. | Jul 2008 | A1 |
| 20080172101 | Bolea et al. | Jul 2008 | A1 |
| 20080177339 | Bolea et al. | Jul 2008 | A1 |
| 20080177348 | Bolea et al. | Jul 2008 | A1 |
| 20080177364 | Bolea et al. | Jul 2008 | A1 |
| 20080177365 | Bolea et al. | Jul 2008 | A1 |
| 20080177366 | Bolea et al. | Jul 2008 | A1 |
| Number | Date | Country |
|---|---|---|
| WO 9718856 | May 1997 | WO |
| WO 9802209 | Jan 1998 | WO |
| WO 9926530 | Jun 1999 | WO |
| WO 9942039 | Aug 1999 | WO |
| WO 9942176 | Aug 1999 | WO |
| WO 9951286 | Oct 1999 | WO |
| WO 0016686 | Mar 2000 | WO |
| WO 0100273 | Jan 2001 | WO |
| WO0176469 | Oct 2001 | WO |
| WO 02026314 | Apr 2002 | WO |
| WO 0226318 | Apr 2002 | WO |
| WO 02070039 | Sep 2002 | WO |
| WO 03018107 | Mar 2003 | WO |
| WO 03076008 | Sep 2003 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20070038255 A1 | Feb 2007 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60368222 | Mar 2002 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10402911 | Mar 2003 | US |
| Child | 11482357 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09963777 | Sep 2001 | US |
| Child | 10402911 | US | |
| Parent | 09671850 | Sep 2000 | US |
| Child | 09963777 | US |
